291 related articles for article (PubMed ID: 33774187)
1. Why are immune adverse events so common with checkpoint inhibitor therapy?
Lyubchenko T; Leung DYM; Goleva E
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
[No Abstract] [Full Text] [Related]
2. A Diverse Range of Cardiac Adverse Events Associated with Immune Checkpoint Inhibitor Therapy.
Murakata Y; Tajiri K
Intern Med; 2022 Jul; 61(14):2099-2100. PubMed ID: 35283387
[No Abstract] [Full Text] [Related]
3. Endocrine adverse effects of immune checkpoint inhibitors.
Walters AGB; Braatvedt G
Intern Med J; 2021 Jul; 51(7):1016-1020. PubMed ID: 34278695
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.
Khan OF; Monzon J
Curr Oncol; 2020 Apr; 27(Suppl 2):S43-S50. PubMed ID: 32368173
[TBL] [Abstract][Full Text] [Related]
5. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
6. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
Fortes BH; Liou H; Dalvin LA
Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
9. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer.
Bakacs T; Moss RW; Kleef R; Szasz MA; Anderson CC
Scand J Immunol; 2019 Dec; 90(6):e12821. PubMed ID: 31589347
[TBL] [Abstract][Full Text] [Related]
10. Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.
Li N; Wang G; Hou X; Tai R; Huang S; He Z; Lei L; Xu S; Yang S
Int Immunopharmacol; 2022 Jul; 108():108803. PubMed ID: 35569432
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
12. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
13. Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.
Nagata S; Hamaji M; Ozasa H; Yamada Y; Ohsumi A; Date H
Clin Lung Cancer; 2022 Jul; 23(5):e321-e324. PubMed ID: 35649818
[No Abstract] [Full Text] [Related]
14. Adverse events induced by immune checkpoint inhibitors.
Perdigoto AL; Kluger H; Herold KC
Curr Opin Immunol; 2021 Apr; 69():29-38. PubMed ID: 33640598
[TBL] [Abstract][Full Text] [Related]
15. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
16. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist.
Furtado VF; Melamud K; Hassan K; Rohatgi S; Buch K
Clin Imaging; 2020 Jul; 63():35-49. PubMed ID: 32120311
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Postow MA; Sidlow R; Hellmann MD
N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
[No Abstract] [Full Text] [Related]
19. The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis.
Zhu H; Huang YV; Wu SM
Med; 2023 Jan; 4(1):13-14. PubMed ID: 36640753
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Immunotherapy-related Adverse Events (IrAE) in Patients Treated With Immune Checkpoint Inhibitors.
Hadfield MJ; Mistry H; Pelcovits A; Bansal R; Andrea S; Chergui A; Ramphal K; Austin M; Khurshid H
Am J Clin Oncol; 2023 Apr; 46(4):183-184. PubMed ID: 36959209
[No Abstract] [Full Text] [Related]
[Next] [New Search]